SCM
PTGX icon

Superstring Capital Management’s Protagonist Therapeutics PTGX Stock Holding History

Superstring Capital Management’s Portfolio PTGX Stock Details PTGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-20,358
Closed -$1.35M – 55
2025
Q3 		$1.35M Buy
+20,358
New +$1.16M 1.33% 27
2025
Q1 		– Sell
-68,892
Closed -$2.66M – 47
2024
Q4 		$2.66M Buy
+68,892
New +$3M 2.3% 13
2024
Q1 		– Sell
-379,143
Closed -$8.69M – 43
2023
Q4 		$8.69M Buy
+379,143
New +$6.63M 6.21% 6

Other funds holding PTGX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Superstring Capital Management's PTGX Position: Q4 2025 in Review

Superstring Capital Management sold out of Protagonist Therapeutics (PTGX) in Q4 2025, closing a stake of 20,358 shares — an estimated $1.35M sold.

Superstring Capital Management first reported a position in PTGX in Q4 2023 and held it in 3 quarters. The position peaked at $8.69M in Q4 2023. 313 funds tracked by Wall St. Rank hold PTGX as of Q4 2025.

  • Superstring Capital Management reported no remaining Protagonist Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Superstring Capital Management sold 20,358 Protagonist Therapeutics shares in Q4 2025, an estimated $1.35M.
  • Superstring Capital Management first reported a position in Protagonist Therapeutics in Q4 2023 and held it in 3 quarters.
  • Superstring Capital Management's Protagonist Therapeutics position peaked at $8.69M in Q4 2023.
  • 313 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q4 2025.

Based on Superstring Capital Management's 13F filing for Q4 2025, filed 17 Feb 2026.